Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based President operating in the Life Science space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Joyce Tung
Vice President, Research of 23andMe
Joyce Tung joined 23andMe in 2007. She has contributed to several of 23andMe’s research publications, and currently develops and manages research projects. she was a National Science Foundation Graduate Research Fellow in the lab of Dr. Renee Reijo Pera. At the University of California, San Francisco she focused on the genetics of egg and sperm development and human fertility. Joyce Tung returned to Stanford University for postdoctoral research in the lab of Dr. Gregory Barsh, where she studied the genetics of human and mouse pigmentation.
Follow Joyce Tung:
About 23andMe: 23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Mark Morris
Vice-President of Research and Development of Elysium
Mark Morris, Elysium Health vice president of research and development, is passionate about bringing an open source model to clinical research in an effort to accelerate advances in human health. By increasing the transparency in scientific research and developing partnerships, a multi-discipline approach may not only fast-track discovery but also lead to a more complete understanding of health issues and more effective treatments. In his role at Elysium, he is responsible for the clinical research program, product development, and commercialization of proprietary technologies. One area of particular interest is the synergy between NAD+ modulation and sirtuin activation, which can be beneficial for a wide range of therapeutic areas. Morris has fifteen years of experience developing new technologies in various industries and has received several patents throughout his career. He has a B.S. in chemical engineering from the University of Akron and resides in New York City.
Follow Mark Morris:
About Elysium: Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs.
Thomas Joyce
President & CEO of Danaher
Thomas Joyce is President and Chief Executive Officer of Danaher Corporation, a position he assumed in September 2014. Thomas is responsible for the company’s strategic vision and leads the development and growth of Danaher’s global science and technology portfolio. Thomas has more than 20 years of Danaher leadership experience. Prior to his appointment as President and Chief Executive Officer, he served as Executive Vice President of Danaher Corporation, responsible for Danaher’s Water Quality platform and Life Sciences & Diagnostics segment. In this role, Thomas increased Danaher’s Water Quality revenue by over $1.5 billion and led the company’s major acquisitions of Beckman Coulter and AB SCIEX. Throughout his tenure, Thomas has also played a key role in developing and evolving the Danaher Business System, Danaher’s common operating philosophy. Thomas began his Danaher career in 1989 as a Project Manager in the Danaher Tool Group, and later transitioned into a manufacturing role. In 1995, Thomas became President of Delta Consolidated Industries. Following this assignment, he became President of Hach Company, the world leader in analytical instrumentation for drinking water and wastewater applications in 2001. In 2002, Thomas became a Group Executive and Corporate Officer with Danaher Corporation, which led to his transition to Executive Vice President in 2006. Prior to joining Danaher, Thomas worked as a management consultant at Anderson Consulting, where he worked with a large number of manufacturing businesses to implement lean tools and optimize transactional processes. Thomas was born and raised on the north shore of Chicago and earned his bachelor’s degree in Economics from the College of the Holy Cross in 1982. He and his wife, Claire, live in Washington, D.C. and have four children.
Follow Thomas Joyce:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
William H. King, IV
Senior Vice President, Strategic Development of Danaher
Mr. King is the Senior Vice President, Strategic Development for Danaher Corporation. Mr. King and his team drive market development, deal sourcing and commercial diligence at Danaher, thus co-owning the M&A process at Danaher with Mr. Daniel Raskas and the Corporate Development team. In addition, he and his team hold responsibility for the strategic planning process, tools and training. Mr. King joined Danaher in 1998 and has held positions as Managing Director of the Special Purpose Systems Motion Control Group, as well as Vice President of Sales and Marketing for the Motion Control Group. Prior to joining Danaher, he held positions of increasing responsibility in live production and logistics for Perdue, Inc. Mr. King has an MBA from Harvard Business School and a BS in Economics from University of Maryland.
Follow William H. King, IV:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Chris Mirabelli
President & CEO of Leap Therapeutics
Dr. Mirabelli has served as the Chairman of our Board of Directors since 2016 and has also served as our President and Chief Executive Officer since our inception in 2011. Dr. Mirabelli has been a managing director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, Dr. Mirabelli served as president of pharmaceutical research and development and member of the board of directors of Millennium Pharmaceuticals, Inc., following its merger with LeukoSite Inc., where Dr. Mirabelli had been serving as president, chief executive officer and chairman of the board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), where he held several positions including senior vice president of research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.
Follow Chris Mirabelli:
About Leap Therapeutics: Leap Therapeutics is a clinical-stage biopharmaceutical company.
Colette Hastings Featherly
Senior Vice President of Oxford Finance LLC
Featherly has over 12 years of experience in the financial services industry, and has been part of the Oxford team since 2010. She is responsible for Oxford’s capital raising, strategic planning and investor relations activities. Prior to joining Oxford, she worked at Dymas Capital Management, a middle market lending affiliate of Cerberus Capital Management. Previously, she held positions at American Capital and CIBC World Markets. Ms. Featherly holds a B.S. in Commerce from the McIntire School of Commerce at the University of Virginia, and an M.B.A. from the Kellogg School of Management at Northwestern University.
Follow Colette Hastings Featherly:
About Oxford Finance LLC, Oxford Finance LLC: Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.
Earl May
Vice President of Lead Discovery of Civetta Therapeutics
Earl May is the Vice President of Lead Discovery at Civetta Therapeutics. He is a former Senior Director Biophysics at Warp Drive Bio, Inc. Mr. May graduated from the University of Maryland Baltimore County with a BA in Biochemistry and received an MPhil and Ph.D.in Molecular Biophysics and Biochemistry at Yale University.
Follow Earl May:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Andrew Cook
Vice President and Head of Chemistry of Civetta Therapeutics
Andrew Cook is the Vice President and Head of Chemistry at Civetta Therapeutics. He was an Associate Director and Director of Medicinal Chemistry at H3 Biomedicine. Mr. Cook graduated from Imperial College London with a Ph.D. in Organic Chemistry and earned a BS in Chemistry at the University of Nottingham.
Follow Andrew Cook:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Jonathan Montagu
President & Chief Executive Officer of HotSpot Therapeutics
Follow Jonathan Montagu:
About Atlas Venture, HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Michael Dabrowski
President of Synthego
Founder & President at Synthego
Follow Michael Dabrowski:
About Synthego: Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Mickey Kertesz
President, CPO & Co-Founder of Karius
Kertesz co-founded Karius in 2014 to bring the pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Prior to that, he was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Dr. Kertesz earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to complete his postdoctoral work in bioengineering at Stanford University, where he developed novel methods for investigating the genetic diversity of human viruses.
Follow Mickey Kertesz:
About Karius: Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Hamid Rategh
Vice President Engineering of Genapsys
Hamid is VP Engineering at GenapSys, joining back in 2012. Hamid has had a successful career developing a wide range of products, from RFICs to adaptive equalizers for optical communication and Mixed-Signal Memory interface products. Prior to joining GenapSys, Hamid was Senior Director of Engineering at Inphi, who acquired his team and product from Scintera Networks. Hamid also cofounded and served as VP of Engineering of Tavanza which was later acquired by Celeritek in 2002 and subsequently by Anadigics in 2003. Hamid holds a PhD in Electrical Engineering from Stanford University, and an MS in Biomedical Engineering from Case Western Reserve University. He earned his BS in Electrical Engineering from Sharif University of Technology.
Follow Hamid Rategh:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Fred Aslan
President & CEO of Artiva Biotherapeutics
Born and raised in Brazil, Fred Aslan is the founder of Adavium Medical (previously known as ADVANCE Medical). He is also affiliated with Venrock, a leading Silicon Valley venture capital firm he joined in 2006. While a full-time investor at Venrock prior to founding Adavium, Fred Aslan was a co-founder and board member of Receptos Pharmaceuticals, a NASDAQ-listed biotech company, which was subsequently acquired by Celgene for more than $8 billion. He also led Venrock’s investment in Zeltiq, a NASDAQ-listed medical device company that was valued at more than $1 billion. Prior to Venrock, he was Director of Business Development and led Investor Relations at CuraGen, a NASDAQ-listed oncology-focused biotech company, and was a strategy consultant with Boston Consulting Group (BCG). He was named the “2014 Business Professional of the Year” by the Brazilian government, recognizing the achievements of Brazilian professionals living outside of Brazil. He is also a board member of Femasys, a US-based women’s health medical device company, and BayBrazil, a Silicon Valley-based not-for-profit organization promoting ties between Silicon Valley and Brazil. Fred Aslan received a B.S. in Biology from Duke University, an M.D. from Yale and an M.B.A. from Harvard.
Follow Fred Aslan:
About Adavium, Artiva Biotherapeutics: Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Rajiv Malik
President & Executive Director of Viatris
Rajiv Malik serves as the president of Viatris and on the company’s board of directors. Originally from India, Malik received a bachelor’s degree and a master’s degree in Pharmaceutical Technology from Punjab University and has 60+ process patents to his credit. Throughout his career, Malik has served in senior leadership roles as head of global regulatory affairs and head of pharma research for Ranbaxy, head of global development and registrations for Sandoz, and CEO of Matrix Laboratories Limited. During his time in this last role, Mylan acquired a controlling stake in Matrix, leading Malik on a path to handle even greater leadership responsibilities at Mylan. Since joining Mylan, Malik held roles including executive vice president, chief operating officer, and head of global technical operations. Malik was integral in developing the strategies for the company’s acquisitions such as Meda , Agila Specialties, and Merck KGaA’s generics business. Importantly, he was also intimately involved in the execution and integration of these and other acquisitions. As the president of Viatris, Rajiv’s responsibilities include overseeing day to day operations, commercial development, medical, IT, quality functions, R&D and the company’s commercial business units. He is especially suited for these varied roles given his unique leadership profile combining a global perspective on healthcare challenges as well as vast experience in scientific, commercial, and financial operations.
Follow Rajiv Malik:
About Viatris: Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
John Putman
President & CTO of Nanotronics Imaging
John Putman is president at Nanotronics Imaging.
Follow John Putman:
About Nanotronics Imaging: Nanotronics Imaging is a microscopy and software company delivering rapid testing and analysis solutions.
Vadim Pinskiy
Vice President of Research and Development of Nanotronics Imaging
Vadim Pinskiy is the vice president of research and development at Nanotronics, where he oversees product development, short-term R&D, and long-term development of AI platforms. Vadim completed his doctorate work in neuroscience, focused on mouse neuroanatomy using high throughput whole slide imaging and advanced tracing techniques. Previously, he earned his master’s in biomedical engineering from Cornell University and his bachelor’s and master’s in electrical and biomedical from the Stevens Institute of Technology. Vadim is interested in applying advanced AI methods and systems to solving practical problems in biological and product manufacturing.
Follow Vadim Pinskiy:
About Nanotronics Imaging: Nanotronics Imaging is a microscopy and software company delivering rapid testing and analysis solutions.
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
David Fortes
Vice President of Operations of Fetch Robotics
David Fortes is the vice president of operations at Fetch Robotics.
Follow David Fortes:
About Fetch Robotics: Fetch Robotics provides the market’s only cloud-driven Autonomous Mobile Robot (AMR) solution for warehousing intralogistics environments.
Greg Verdine
Co-Founder, President & CEO, CSO of LifeMine Therapeutics
Greg Verdine is the Founder of Gloucester Marine Genomics Institute & he attended Massachusetts Institute of Technology in 1986.
Follow Greg Verdine:
About FogPharma, Gloucester Marine Genomics Institute, Harvard Medical School, Harvard University, LifeMine Therapeutics, Massachusetts Institute of Technology, Wave Life Sciences: Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology.
Cuthbert Simpkins
Chief Innovation Officer and President of Vivacelle Bio
Cuthbert Simpkins is the inventor of Vivacelle and the President of Vivacelle Bio, Inc. He is also a trauma surgeon and scientist. Cuthbert Simpkins has over thirty years of experience as a surgeon including serving as Director of the Trauma Program at LSU Health Sciences Center in Shreveport, LA. He finished his undergraduate studies at Amherst College with honors in Chemistry and graduated from Harvard Medical School in 1974. Cuthbert Simpkins completed his surgical training in 1980 at St. Luke’s Hospital in New York City and Downstate Medical Center in Brooklyn. He did research fellowships at Boston University School of Medicine and the Naval Medical Research Institute. He achieved the rank of Commander and received two commendations for excellence in research while serving in the U.S. Navy which included several scientific discoveries and publications.
Follow Cuthbert Simpkins:
About Vivacelle Bio: Vivacelle Bio is a clinical stage biotech company focused on bringing to market a new paradigm in resuscitation fluids.
Michael T. Heffernan
President , CEO & Chairman of the Board of Collegium Pharmaceutical
Michael Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain. He was also previously the founder, President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses and was responsible for the spin-off of this business to create PreCision Dermatology. Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold. He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company. Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in a number of healthcare companies. He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company and PreCision Dermatology. Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
Follow Michael T. Heffernan:
About AvengeBio, Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Heow Tan
Vice President of Technical Operations of Collegium Pharmaceutical
Heow Tan has worked in the pharmaceutical industry for 25 years. He joined Collegium Pharmaceutical in 2006. He is responsible for CMC Product Development and Manufacturing activities. His experience in CMC includes working with oral, semi-solid and parenteral products, and successfully taking a product from pre-clinical to FDA and European approval. Prior to Collegium, he worked at Praecis Pharmaceuticals Inc., Waltham, Massachusetts as Vice President of Industrial Operations and Development;, He has also served as the Director of Manufacturing Operations for SciClone Pharmaceuticals Incorporated, San Mateo, California. Heow started his career in the Pharmaceutical industry working for Syntex Laboratories in Palo Alto, California, serving as the Manager of Manufacturing Engineering and Manager of Materials Control. He obtained his M.S. in Engineering from the Ohio State University, Ohio, and his M.B.A. from the University of Santa Clara, California.
Follow Heow Tan:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Joseph Ciaffoni
President and Chief Executive Officer of Collegium Pharmaceutical
Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Joe Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Joe Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Joe Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.
Follow Joseph Ciaffoni:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Patrick Lindsay
Executive Vice President of United Biosource Corporation
Patrick Lindsay serves as President of UBC, guiding the company’s mission, vision, values, and strategic imperatives. He is responsible for clinical operations, business growth strategy, sales and marketing, and acquisition support. Patrick served as one of the early developers of the organization, which grew out of a passion for innovation and commitment to working with pharmaceutical and biotech organizations in providing safety, efficacy, and value of pharmaceutical and medical products. Patrick has been a leader in the healthcare and pharmaceutical services industry for more than 25 years. During his career, Mr. Lindsay has held senior management positions in such diverse areas as clinical stage operations, data management, biostatistics, information technology, marketing, and business development. He earned his Bachelor of Science in management from Rosemont College in Pennsylvania. Patrick is unconditionally focused on establishing high-level customer relationships and partnering with customers to match UBC service offerings to their research development projects, from both strategic and execution perspectives. Patrick was featured on the cover of the December 2013 edition of Pharmaceutical Executive: Pharma’s Life Partner: An Interview with United BioSource’s Patrick Lindsay.
Follow Patrick Lindsay:
About United Biosource Corporation: United BioSource is a medical and scientific affairs company developing and commercializing products for life science companies worldwide.
Annette Stemhagen
Senior Vice President, Safety, Epidemiology, Registries & Risk Management of United Biosource Corporation
Annette Stemhagen, DrPH, FISPE, provides strategic consultative services to pharmaceutical and biotechnology clients in epidemiology, safety surveillance, and risk management. In addition, she assists other UBC groups in developing and implementing creative and innovative study design solutions to meet client needs. Dr. Stemhagen has more than 25 years of public health epidemiological research experience, including 15 years in safety surveillance of pharmaceutical, biotech, and vaccine products. Her specific expertise is in the design, implementation, and analysis of epidemiologic studies, registries, large streamlined safety studies, and actual use and observational studies for products in Phase IIIb and postapproval. Further, Dr. Stemhagen has designed and evaluated risk assessment studies, including more than 50 regulatory-mandated long-term safety studies. She has also developed Risk Evaluation and Mitigation Strategies (REMS) risk minimization programs and risk management evaluation studies. Dr. Stemhagen received her undergraduate degree from the University of Pennsylvania, and her master’s and doctoral degrees from the University of Pittsburgh Graduate School of Public Health in Epidemiology. She holds adjunct faculty appointments at both the University of Pennsylvania School of Medicine Center for Epidemiology and Biostatistics and the Temple University School of Pharmacy. Dr. Stemhagen is a Fellow of the International Society for Pharmacoepidemiology and is active in the Drug Information Association. In 2004, she was appointed as the industry representative to the FDA Drug Safety and Risk Management Advisory Committee.
Follow Annette Stemhagen:
About United Biosource Corporation: United BioSource is a medical and scientific affairs company developing and commercializing products for life science companies worldwide.
Gene Hung
Co-founder and Senior Vice President of XinThera
Gene Hung is a Co-founder and Senior Vice President at Xinthera Inc.
Follow Gene Hung:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Qing Dong
President & CSO of XinThera
Qing Dong is a President & CSO, of Xinthera Inc.
Follow Qing Dong:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Arthur Levin
Executive Vice President, Research & Development of Avidity Biosciences
Arthur A. Levin, Ph.D., is miRagen’s Executive Vice President of Research and Development. Dr. Levin is a drug development veteran having spent more than 30 years in the pharmaceutical industry, of which more than 15 years were in the area of research and development of RNA-targeting therapeutics. He is a recognized world expert on the preclinical and clinical development of oligonucleotide-based therapeutics. Prior to joining miRagen Therapeutics, Dr. Levin was Chief Development Officer of Santaris Pharma A/S, where he led the efforts on the first microRNA-targeting therapeutic in Phase 2 clinical trials, miravirsen. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA.Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. His expertise was instrumental in advancing more than a dozen oligonucleotide drugs from basic research to clinical development in areas such as neuromuscular diseases, infectious diseases, metabolic disorders, cardiovascular disease, and cancer. He joined Isis from Hoffmann-La Roche Inc., where he was Research Leader. Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, New York, and a B.S. in Biology from Muhlenberg College.He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He was the recipient of the Scala Award for Industrial Toxicology and is the author of more than 50 papers and book chapters.
Follow Arthur Levin:
About Avidity Biosciences, Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Andy Geall
Vice President of Formulations and Chemistry of Avidity Biosciences
Andy Geall is the VP of formulations and chemistry at Avidity Biosciences.
Follow Andy Geall:
About Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Frank Laukien
President & CEO of Bruker
Frank Laukien is the Chairman, President and CEO of Bruker Corporation and he is also President of Bruker Daltonics. Dr. Laukien holds a B.Sc. in physics from MIT, and a Ph.D. in chemical physics from Harvard University.
Follow Frank Laukien:
About Bruker, Swammerdam Institute for Life Sciences: Bruker is a manufacturer of analytical and medical instruments covering NMR, ESR, FT-IR, X-RAY spectroscopy.
Zachary Hornby
Chief Executive Officer & President of Boundless Bio
Zachary Hornby brings a dozen years of life sciences business experience to Ignyta. Prior to joining Ignyta, Mr. Hornby was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Mr. Hornby has also served in various business and commercial roles at Halozyme Therapeutics (NASDAQ: HALO), Neurocrine Biosciences (NASDAQ: NBIX) and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an M.B.A. from Harvard Business School.
Follow Zachary Hornby:
About Boundless Bio, City Hill Ventures: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Kathryn Fink
Vice President, Global Human Resources of Stryker
M. Kathryn (Katy) Fink was named Vice President, Global Human Resources, in January 2016. Ms. Fink is responsible for all human resources policies, practices, planning, direction and activities, including Talent Acquisition, Talent Development, Total Rewards and HR Shared Services. Ms. Fink began her career with Stryker in 2013 as Vice President, Talent Management and was promoted in 2015 to Vice President, Human Resources, MedSurg and Neurotechnology Group. Prior to joining Stryker, she held a number of HR roles of increasing scope and complexity at Cintas Corporation, Ethicon Endo-Surgery, a division of Johnson & Johnson. Ms. Fink holds a Bachelor of Science degree from Kenyon College and Master’s degree in human resource management (HRM) at Rutgers’ School of Management and Labor Relations.
Follow Kathryn Fink:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Yin Becker
Vice President, Chief Corporate Affairs Officer of Stryker
Follow Yin Becker:
About Stryker, Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Eugene A. Gregerson
Vice President R&D of Stryker
Eugene A. Gregerson is the Vice President R&D at Stryker Spine.
Follow Eugene A. Gregerson:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Elizabeth A. Staub
Vice President, Regulatory Affairs and Quality Assurance of Stryker
Elizabeth A. Staub was named Vice President, Regulatory Affairs and Quality Assurance, in April 2006. Ms. Staub is responsible for overseeing Stryker’s compliance with worldwide product quality and regulatory requirements, including FDA and other regulatory bodies. Ms. Staub began her career with Stryker in April 1989 and held a number of quality, regulatory and operational positions within the Company’s Orthopaedics division, including Manager, Quality Assurance; Team Leader for the packaging cell; Manufacturing Team Leader for the external support cell; Director of the Knee Steering Team; Vice President, Quality Assurance, Regulatory Compliance and Clinical Research; and Director of the Business Process Excellence Project. She then served as Director, Regulatory Affairs and Quality Assurance, for the Company from 2005 to 2006. Prior to joining Stryker, Ms. Staub spent six years with Baxter Healthcare in a variety of quality assurance positions. Ms. Staub holds a B.S. in Medical Technology from York College of Pennsylvania.
Follow Elizabeth A. Staub:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Irene B. Corbe
Vice President, Internal Audit of Stryker
Irene B. Corbe joined Stryker in April 2014 as Vice President, Internal Audit. Ms. Corbe reports to the Audit Committee of Stryker’s Board of Directors. In this role, Irene oversees Stryker’s financial audit activity which is a critical component of the corporate governance structure. Irene joined Stryker with 25 years of experience in internal audit, finance and accounting in various roles of increasing responsibilities. Most recently, Ms. Corbe was the Vice President, Internal Audit at Whirlpool Corporation. Ms. Corbe received her Masters of Business Administration from Oakland University and her undergraduate degree in business administration from the University of Michigan. She is also a Certified Public Accountant.
Follow Irene B. Corbe:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Bronwen R. Taylor
Vice President, Risk Management of Stryker
Bronwen Taylor was named Vice President, Compliance and Risk Management in August 2013. Ms. Taylor is responsible for the coordination of Stryker’s compliance programs and liability avoidance efforts worldwide. Ms. Taylor joined Stryker in March 2000 as Chief Financial Officer for Stryker South Pacific. She subsequently served as Vice President and Chief Financial Officer and as Director, Operations, of Stryker South Pacific. Ms. Taylor relocated to Kalamazoo in January 2006 to become Stryker’s first Chief Compliance Officer. In 2007 Ms. Taylor was promoted to Vice President of Internal Audit and Compliance and in 2010 she moved to Newbury, UK to become Vice President, Chief Financial Officer for our European operations. Prior to joining Stryker, Ms. Taylor held senior finance positions in financial services and global mining companies in Australia. She started her career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers) in Australia and held various positions in the Australian and United Kingdom firms. Ms. Taylor holds a B.B.A. from the Queensland University of Technology, Australia, and an M.B.A. from Monash University, Victoria, Australia. She is also a fellow of the Institute of Chartered Accountants in Australia.
Follow Bronwen R. Taylor:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
William E. Berry Jr.
Vice President, Corporate Controller of Stryker
Follow William E. Berry Jr.:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
David G. Furgason
Vice President, Tax of Stryker
Follow David G. Furgason:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
John Casey
Co-Founder, Vice President, Head of Business Development of Senda Biosciences
John is the Co-Founder, Vice President, and Head of Business Development of Senda Biosciences. Before that, he joined Flagship Pioneering in 2015 as an associate after completing the VentureLabs Fellows program. At Flagship, John works as part of a venture creation team, exploring innovative ideas and opportunities, and developing critical scientific and business components that will lead to the firm’s next breakthrough startups. Before joining Flagship, John earned his doctorate in biological engineering in Angela Belcher’s lab at MIT, where he designed and developed thermostable de novo enzymes on viral capsid proteins. His work led to a collaboration with the pharmaceutical industry to develop cleaner, more versatile manufacturing processes. John was an active contributor to Boston’s entrepreneurial community while a graduate student. As associate director for MIT’s $100K Entrepreneurship Competition, he partnered with local and national businesses to raise the competition’s six-figure annual budget. He developed a new prototyping contest with increased resources and direct support for student entrepreneurs. He subsequently served as Chair of the $100K’s board of directors. Additionally, John was a communication fellow in the Biological Engineering Department and served as the biotechnology editor for the MIT Entrepreneurship Review. John received his B.S. in biological engineering from Louisiana State University, where he was a Goldwater Scholar and named the top graduating student in his class. His thesis research explored site-specific oligonucleotide modifications. John was active in LSU’s Student Government, president of the campus Habitat for Humanity chapter, and a co-founder and president of an organization for Mandarin Chinese speakers.
Follow John Casey:
About Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Michael McKenna
President & COO of Quantum SI
Michael McKenna is the President and Chief Operating Officer of Quantum-Si since December 2014. Prior to joining Quantum-Si, Dr. McKenna served as Vice President, R&D at Life Technologies Corporation, a global biotechnology company, from August 2011 to July 2014, and as a consultant to Life Technologies from February 2011 to August 2011. Dr. McKenna received his B.S. in molecular biology and German from Carnegie Mellon University and his Ph.D. in biology from Yale University.
Follow Michael McKenna:
About Quantum SI: Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.
Andrew Scott
Vice President of Corporate Development of Citius Pharmaceuticals
Follow Andrew Scott:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Gary Talarico
Executive Vice President of Operations of Citius Pharmaceuticals
Gary Talarico has served as EVP, Operations since March 2016. Gary has successfully built and led all commercial activities for a number of start-up companies. Most recently he was a founder, partner and Executive Vice President of Leonard Meron Biosciences; he was instrumental in acquiring its lead product. Previously, Gary served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Gary was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, Gary was Executive Vice President of Business Development for Ventiv Health. His earlier experience included Vice President of Sales for Medicis Pharmaceutical at its initial start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Gary is a graduate of Lewis University.
Follow Gary Talarico:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Alan Lader
Vice President of Clinical Operations of Citius Pharmaceuticals
Alan Lader joined Citius Pharmaceuticals as Vice President of Clinical Operations in 2016
Follow Alan Lader:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Paul Grayson
President and CEO of Bird Rock Bio
Paul Grayson is the Partner at Versant Ventures.
Follow Paul Grayson:
About AccessBioVentures, Bird Rock Bio, Tentarix Biotherapeutics: Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators.
Ashutosh Singhal
Co-Founder and President of Benchling
Ashutosh Singhal previously worked on Twitter Ads and founded hotspots.io. Singhal studied Computer Science and Math at MIT and did research in optogenetics and functional genomics. He loves distance running and IPAs.
Follow Ashutosh Singhal:
About Benchling: Benchling is a cloud-based software platform for biology researchers and research and development organizations.
Jaswinder Chadha
President & CEO of Axtria
Jassi founded Axtria with the vision of building cutting-edge analytics and software solutions that will help global companies to effectively manage and get insights from big data. He is a pioneer in building advanced decision support software.He has worked closely with over 100 global companies to improve effectiveness of their commercial operations. Pharmaceutical Management Science Association (PMSA) awarded Jassi with prestigious lifetime achievement award in 2014. This is among several other accolades. Jassi also serves on the Board of many diverse organizations like TIE Global, Ocular Therapeutics, SpectraMedix and others.
Follow Jaswinder Chadha:
About Axtria: Axtria is a big data analytics software and services company for the Life Sciences industry.
David M. Epstein
Founder, President & Chief Executive Officer of Black Diamond Therapeutics
David M. Epstein, PhD is founder & CEO of Black Diamond Therapeutics. David is a biopharma leader and executive who has successfully led large and small R&D teams in academic, virtual, start-up, mid-size and global large-pharma settings. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. David was Chief Scientific Officer at Astellas/OSI Pharmaceuticals, and previously a founder of Archemix Corp. Most recently Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology at Duke-NUS Medical School, Singapore, David founded and built Duke-NUS’s Centre for Technology & Development (CTeD). The Centre has developed a pipeline of innovation projects, completing 2 product-development biopharma partnerships, and 7 spin-outs from its technologies. David’s research focuses on RNA splicing and immune-tumor cell interactions in cancer. He earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship leading a collaboration in protein structure, function and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla.
Follow David M. Epstein:
About Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Elizabeth Buck
Founder, Executive Vice President of Black Diamond Therapeutics
Elizabeth Buck is co-founder and Executive VP, Discovery & Translational Sciences for Black Diamond Therapeutics. Dr. Buck was instrumental in developing Black Diamond’s MAPing platform though which she made critical discoveries leading our understanding of the properties of allosteric mutations in oncogene activation. Dr. Buck has over 15 years of experience in oncology therapeutics in biotechnology and large pharma industries. Her expertise and productivity are evidenced by more than 40 peer reviewed publications and patents. Prior to joining Black Diamond, Dr. Buck was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, where she led discovery and translational research to advance a series of oncology programs to clinical development. During this role Dr. Buck managed multidisciplinary global teams and spearheaded major academic collaborations to progress programs to IND. Dr. Buck received her undergraduate degree in physics from the University of New Hampshire, Ph.D. in cellular and molecular biology from New York University / Mount Sinai School of Medicine, and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals.
Follow Elizabeth Buck:
About Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Wes Kaupinen
President and CEO of Palvella Therapeutics
Wes Kaupinen has served as president and CEO since Palvella’s inception. Mr. Kaupinen brings more than 15 years of entrepreneurial life sciences experience as an operating executive and early stage investor. Prior to Palvella, Mr. Kaupinen was a senior executive at Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, where he served as senior vice president of corporate development and commercialization. While at Insmed, he led the global corporate development and U.S. commercial functions, with key responsibilities including corporate strategy, acquisitions and in-licensing, R&D pipeline strategy, patient advocacy, marketing, and pricing and reimbursement. Previously, Mr. Kaupinen was a principal at Quaker Partners, a life sciences venture capital firm with $700mm under management, where he worked on several public and private venture capital investments in the life sciences space. At Quaker, he was responsible for the recruitment of new senior leadership to Insmed to execute on the company’s rare disease strategy, and he was involved in Quaker’s investments in Horizon Pharma (NASDAQ: HZNP) and Achillion Pharmaceuticals (NASDAQ: ACHN). In addition, he led Quaker’s Series A investments in Intact Vascular (backed by NEA, Quaker, and HIG) and TELA Bio (backed by OrbiMed, Quaker, and Signet), playing a key role in the investor syndication, leadership recruitment, and corporate strategy development for each. Mr. Kaupinen has operating experience at two Johnson & Johnson operating companies, including Cordis Cardiology where he worked on the CYPHER sirolimus-eluting stent, the first drug-eluting stent ever launched which leveraged the multi-modal therapeutic properties of sirolimus to significantly improve outcomes for patients with coronary ischemic disease. Earlier in his career, Mr. Kaupinen was an associate at Apax Partners, a global private equity firm, and an analyst in the Life Sciences Investment Banking Group at Robertson Stephens. Mr. Kaupinen has served as a board director or observer for more than ten companies, including Palvella, Intact Vascular, and TELA Bio. He is currently the chief strategy officer for The Castleman Disease Collaborative Network, a non-profit dedicated to finding a cure for Castleman Disease, a rare autoimmune disease. Mr. Kaupinen earned an M.B.A. from The Wharton School of the University of Pennsylvania where he was the recipient of the William L. Kissick MD Scholarship Award. He holds a B.A. in economics from The University of Virginia.
Follow Wes Kaupinen:
About Palvella Therapeutics: Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.
Todd Hembrough
President of Proteomics of NantOmics
Todd Hembrough, Ph.D. is the President of Proteomics at NantOmics where he oversees R&D, operations, and the clinical proteomics laboratory. Todd obtained his Ph.D. in Biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, Todd was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways. Todd later became the Chief Scientific Officer and Head of R&D at OncoPlex Diagnostics and Expression Pathology where he led the development and commercial launch of the first quantitative proteomic assays performed on formalin-fixed, paraffin-embedded tissue.
Follow Todd Hembrough:
About AstraZeneca, NantOmics, OncoPlexDx, OncoPlexDx: NantOmics develops cloud-based molecular profiling tools that help guide cancer patients.
Deborah (Deb) Autor
Senior Vice President, Head of Strategic Global Quality & Regulatory Policy of Mylan
Deb (Deborah) Autor is Mylan’s Senior Vice President, Head of Strategic Global Quality & Regulatory Policy. Autor joined Mylan after more than a decade of service at the FDA. Deb is a transformative innovator with a unique, multifaceted view of the biopharmaceutical industry built on decades of domestic and global public and private sector experience. Autor’s expertise is highly respected in the industry, with a vast personal network and many board memberships.
Follow Deborah (Deb) Autor:
About Mylan: From 1961-2020, Mylan offered a broad portfolio of generic and specialty pharmaceutical products.
Jonathan Collins
Vice President, Manager & Head of eCommerce of Mylan
Jonathan Collins is Vice President & Head of eCommerce at Mylan. He is Member of the Board of Directors at Carlisle.
Follow Jonathan Collins:
About Mylan: From 1961-2020, Mylan offered a broad portfolio of generic and specialty pharmaceutical products.
Steven Kelly
President & Chief Executive Officer of Carisma Therapeutics
Follow Steven Kelly:
About Carisma Therapeutics: Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Rolf Ehrhardt
Co-Founder , President and Chief Executive Officer of BioCision
Dr. Rolf Ehrhardt co-founded BioCision in 2007, after more than 25 years of experience in leadership and innovation in medical research and product development. Prior to growing BioCision into the leading provider of temperature-sensitive sample and drug handling solutions, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery and immuno-therapeutics development at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his M.D. and Ph.D. with distinction from the Technical University of Munich, Germany.
Follow Rolf Ehrhardt:
About BioCision: BioCision develops laboratory tools to standardize pre-analytical sample handling, cryopreservation, and storage.
Steven Battista
Vice President of Anzu Partners
Steven Battista is the Vice President at Anzu Partners.
Follow Steven Battista:
About Anzu Partners: Anzu Partners is an investment firm that invests in industrial and life science technology companies.
Patrick Daly
Global Vice President & General Manager of IQVIA
Mr. Daly has over 20 years of experience in medical device sales, marketing, international marketing and leadership positions throughout the Johnson & Johnson organization including Ethicon Endo-Surgery, Ethicon Products, J&J Medical Australia/New Zealand, J&J Medical Asia Pacific and Cohera Medical, Inc.® Within Johnson & Johnson, he held positions of increasing responsibility in marketing, international marketing and sales. He successfully launched a surgical technology business in Australia and created and implemented the first-ever regulatory review of safety and efficacy of that new technology by the Australian Government. He continued his Johnson & Johnson entrepreneurial-like career track as a marketing leader in J&J Medical Asia Pacific by creating and implementing training and development programs in China, India, Korea, Singapore, and the Philippines. Mr. Daly started Cohera Medical in January 2006 and led three successful funding rounds of over $57.8M in capital from private investors to facilitate Cohera Medical’s lead product TissuGlu® Surgical Adhesive through the FDA approval process for medical devices. Prior to joining Cohera Medical and Johnson & Johnson, Mr. Daly spent over four years on active duty in the U.S. Army as a field artillery officer serving around the world. A native of New York, he is a graduate of the U.S. Military Academy at West Point where he received a B.S. in Engineering with a concentration in Latin American Studies. He played varsity lacrosse during his four years at West Point and was an All-American. Mr. Daly serves on several Boards, including the Emerging Growth Company Council (EGCC) for the Advanced Medical Technology Association (AdvaMed), the Pittsburgh Technology Council and Girls Hope, a nonprofit that provides a well-balanced, nurturing home and quality education through college for academically capable girls. He is also a member of the Young Presidents Organization.
Follow Patrick Daly:
About IQVIA: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Rajneesh Patil
Vice President, Digital Strategy & Innovation of IQVIA
Rajneesh Patil is the Vice President, Digital Strategy & Innovation at IQVIA.
Follow Rajneesh Patil:
About IQVIA: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Christina Bodurow
Vice President, Strategic Operations, Data Science, Statistics, and Regulatory of IQVIA
Follow Christina Bodurow:
About IQVIA, IQVIA: IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.
Michael Laird
Vice President of Genentech
Vice President, Cell Culture & BioProcess Operations Genentech, Inc.
Follow Michael Laird:
About Genentech: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Ira Mellman
Vice President, Cancer Immunology of Genentech
Vice President of Cancer Immunology at Genentech.
Follow Ira Mellman:
About Genentech, University of California, San Francisco: Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients.
Michael Henry
Senior Vice President and General Manager of Consumer Genomics of Centrillion Technologies
Michael Henry is a Senior Vice President and General Manager of Consumer Genomics at Centrillion Biosciences, Inc. He is also an Advisor of Berkeley SkyDeck.
Follow Michael Henry:
About Centrillion Technologies: Centrillion Biosciences develops genomics and DNA analyses technology for personalized medicine, life sciences research, and bioinformatics.
Russell Cox
President & CEO of Epirium
Russell J. Cox was appointed our Executive Vice President and Chief Commercial Officer in March 2012. He has served in a variety of escalating senior management roles since joining the company in 2010. From January 2009 to January 2010, he was Senior Vice President and Chief Commercial Officer of Ipsen Group and from 2007 until December 2008, he was Vice President of Marketing at Tercica, Inc. (acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, he was with Scios Inc. (acquired by Johnson and Johnson later in 2003), where he also held the role of Vice President, Marketing. Prior to 2003, Russell Cox was with Genentech, Inc. for 12 years, where he was a Product Team Leader (PTL) responsible for the Growth Hormone franchise and led numerous product launches as a Group Product Manager. Russell Cox received a B.S. in Biomedical Science from Texas A&M University.
Follow Russell Cox:
About Epirium: Epirium Bio is a clinical stage bio pharmaceutical company.
Mary Godwin
Vice President Operations of Nautilus Biotechnology
Follow Mary Godwin:
About Nautilus Biotechnology: Nautilus Biotechnology offers a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
Daniel Grosu
Founder, Chief Executive Officer & President of PetDx
Dr. Daniel Grosu is the Founder and Managing Partner of GenoPraxis, LLC – a San Diego based specialty consultancy dedicated to enabling the practical implementation of genomic testing technologies. He is also an active angel investor, and sits on the Life Science committee of Tech Coast Angels (San Diego). Dr. Grosu previously served as Sequenom’s last Chief Medical Officer (until the company’s acquisition by LabCorp) and as Illumina’s first Chief Medical Officer. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE Marking of the MiSeqDx platform and associated cystic fibrosis assay – the world’s first NGS-based in-vitro diagnostic (IVD) product. Earlier in his career, Dr. Grosu held positions of increasing responsibility in medical affairs and clinical development at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, Missouri, and an MBA from the University of Oxford, UK.
Follow Daniel Grosu:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
John Cumbers
Founder & Executive President of SynBioBeta
John Cumbers is the founder of SynBioBeta, an activity hub for synthetic biology startup companies, industry and investors. He received his PhD in Molecular Biology, Cell Biology, and Biochemistry from Brown University. He has a masters degree in bioinformatics from the University of Edinburgh in Scotland and an undergraduate degree in computer science from the University of Hull in England. He founded the iGEM (International Genetically Engineered Machines competition) team at Brown University in 2005, was an iGEM ambassador to China in 2006/2007 and has been working in the field of synthetic biology and resource utilization in space at NASA Ames since 2008. John led the Planetary Sustainability Collaboratory at the NASA Ames Space Portal where he worked on partnerships that bring new technologies to bear on sustainability challenges on Earth and in space. In 2010, John was the recipient of a National Academies Keck Futures Initiative award to understand the role that synthetic biology could play in NASA’s missions. He has also been involved in multiple start-ups producing food for space and using microbes to extract lunar and martian resources. He was at NASA for 7 years working on these issues and was instrumental in starting NASA’s program in synthetic biology. Thought leader, and community builder, and consultant for both the public and private sector, John is passionate about using biotechnology to make a better world through sustainable technologies. As an authority on the topic, John has built communities in the space synthetic biology arena, published multiple papers on food production in space, terraforming, and the genetics of extremophiles. Constantly educating and connecting those around him, John is a person to know in the industry. His company, SynBioBeta, brings together the entire community together several times each year and gives anyone the opportunity to meet with the bright minds building and shaping the bioeconomy — from venture capitalists and angel investors to entrepreneurs and industry thought leaders.
Follow John Cumbers:
About SynBioBeta: Leading community of innovators, investors, engineers, and thinkers who share a passion for advancing synthetic biology
Nick Macris
Vice President, Environment Sector of Precigen
Mr. Macris brings 15 years of business and technical experience in the natural product, industrial and specialty technical industries to Intrexon. Macris joins the company from Marrone Bio Innovations, an early-stage biopesticide company focused on natural product solutions for disease and pest management in plants and aquatic systems where he was Vice President of Business Development. Macris has worked in various roles at several other agricultural and environmental biotech companies, including business development at Purifics ES Inc., corporate development and mergers and acquisitions at FMC Corporation, and corporate level platform development as well as business development activities to establish a biopesticide portfolio at Rohm & Haas. Prior to pursuing his M.B.A., Macris worked in the specialty chemical division and the tape product engineering group at 3M Canada. Macris earned an M.E.Sc. in Chemical and Biochemical Engineering from the University of Western Ontario and an M.B.A. from the Richard Ivey Business School in London, Canada.
Follow Nick Macris:
About Precigen, Purifics ES Inc, Rohm & Haas: Precigen is a life sciences company researching and developing bio-therapeutic control systems to minimize toxicity.
Carol Spector Dingle
Vice President Technical Services of On Assignment
Carol Dingle has held executive-level positions in software development and IT operations for more than 18 years. As Vice President of Technical Services at On Assignment, Inc., she oversees the technical needs of an international staffing organization with multiple divisions across the United States and Europe. Prior to her current position, she was Vice President of Operations and Infrastructure at banking technology provider Digital Insight.
Follow Carol Spector Dingle:
About On Assignment: On Assignment is a provider of highly skilled, hard-to-find professionals in the growing technology, life sciences, and creative sectors.
Thomas J O’Brien
President and CEO of Axion BioSystems
Tom O’Brien was most recently a senior executive at Philips Medical Systems, a division of Royal Philips, after the sale of Intermagnetics General Corporation (NASDAQ: IMGC). At Intermagnetics, he held the role of Executive Vice President, Corporate Development and President, Invivo Medical Devices. Prior to that, he has had various senior executive positions in both public and private companies, in the US and abroad. Mr. O’Brien holds a Bachelor’s Degree in Industrial Engineering from Georgia Tech and an MBA from the University of Chicago.
Follow Thomas J O’Brien:
About Axion BioSystems: Axion Biosystems is a life science company developing technologies that solve problems related to human heart and brain activity.
Ed Schutter
President & CEO of Arbor Pharmaceuticals
Ed Schutter has over 25 years of pharmaceutical industry experience and served as President and Chief Operating Officer of Sciele (Shionogi) Pharmaceuticals prior to joining Arbor. Prior to his Sciele experience, Ed served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Prior to joining the industry, Ed owned and operated an independent retail pharmacy in Roswell, GA. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, Ga. Ed has a BS in Pharmacy from Mercer University and an MBA from Kennesaw State University.
Follow Ed Schutter:
About Arbor Pharmaceuticals, Shionogi, Solvay Pharmaceuticals: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Mary Lou Freathy
Vice President of Quality & Manufacturing of Arbor Pharmaceuticals
Mary Lou has more than 25 years of pharmaceutical experience in quality, regulatory affairs, and manufacturing compliance including over 10 years supporting the growth of life science companies. Mary Lou was previously Senior Vice President of Quality, Regulatory Affairs, and Chief Compliance Officer of G&W Laboratories. Prior to that, she held several executive managerial positions at Paddock Laboratories, Pliva, Inc., and Dey Laboratories where she started her pharmaceutical career. Mary Lou belongs to several professional societies including RAPS, PDA, ISPE, and ASQ. She holds a J.D. from the Empire School of Law, and a B.A. in Chemistry from the State University of New York. She is also a Certified Compliance Professional.
Follow Mary Lou Freathy:
About Arbor Pharmaceuticals: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Thom Rowland
Vice President, Commercial Operations of Arbor Pharmaceuticals
Thom Rowland is an industry veteran who started his career as a sales representative for UCB Pharmaceuticals. Thom later held various marketing positions with UCB prior to taking the position of head of marketing for Scandipharm. He played a lead role in turning the Scandipharm business around prior to its sale to Axcan Pharmaceuticals. Thom then served as a Vice President of Sales and Marketing for several business units at Solvay Pharmaceuticals where he was again instrumental in turning around an underperforming area. Thom was one of the founders of Ventrus Biosciences which completed a successful IPO in 2010.
Follow Thom Rowland:
About Arbor Pharmaceuticals, Axcan Pharmaceuticals, Solvay Pharmaceuticals, UCB: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Steven Caras
Vice President of Clinical Development of Arbor Pharmaceuticals
Dr. Steven Caras is a gastroenterologist and biomedical engineer. He has a Bachelors degree in Chemical Engineering from Arizona State University and Masters and Ph.D. degrees in Bioengineering from the University of Utah in Salt Lake City. Steve obtained his medical degree from the University of Miami. He did his residency training in internal medicine at Washington University in St. Louis and his gastroenterology fellowship at University of Virginia in Charlottesville. After his gastroenterology fellowship, Steve worked as a medical reviewer in the Cardio-Renal Division of FDA, where he was mainly involved in antihypertensive and antiarrhythmic drugs. Steve currently volunteers for a local chamber of commerce which evaluates pharmaceutical and medical device companies and provides these companies with essential development, regulatory, and business feedback. Steve is also an Adjunct Professor at the University of Georgia’s College of Pharmacy’s Regulatory Affairs and Clinical Trials Graduate Program.
Follow Steven Caras:
About Arbor Pharmaceuticals: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Philip Ma
Chief Business Officer and President of Seer
Philip Ma is the Chief Executive Officer, President & Founder of PrognomiQ.He attend to the Massachusetts Institute of Technology in 1988.
Follow Philip Ma:
About PrognomiQ, Seer: Seer is a biotechnology company that offers tools and solutions related to the field of proteomics.
James A. Hayward
Chairman, President & Chief Executive Officer of Applied DNA Sciences
Dr. James A. Hayward is Chairman, President, and CEO of Applied DNA Sciences. With over 20 years of experience in the biotechnology, pharmaceutical, life science and consumer product industries, Dr. Hayward is actively involved in the global effort to ensure the authenticity of products and the protection of global supply chains from counterfeiting and diversion. Patented and applied in over a billion products throughout the world, the Company’s SigNature® DNA tags are unique sequences that can help preserve the quality and integrity of products from pharmaceutics to cosmetics. Dr. Hayward received his Bachelor’s degree in Biology and Chemistry from the State University of New York at Oneonta in 1976, his Ph.D. in Molecular Biology from the State University of New York at Stony Brook in 1983, and an honorary Doctor of Science from the same institution in 2000. He was one of the founding principals and research director of Europe’s first liposome company, Biocompatibles Ltd. From 1984 to 1989, he was responsible for product development at Esteé Lauder Companies. In 1990, Dr. Hayward founded The Collaborative Group, a provider of products and services to the biotechnology, pharmaceutical and consumer-product industries based in Stony Brook. For 14 years, he served as Chairman, President and CEO of Collaborative, spawning multiple businesses including The Collaborative BioAlliance, a contract developer and manufacturer of human gene products, that was sold to Dow Chemical in 2002, and Collaborative Laboratories, a service provider and manufacturer of ingredients for skincare and dermatology was sold to Engelhard (now BASF) in 2004. Dr. Hayward has been twice named “Entrepreneur of the Year;” in 2002 by Inc. Magazine and in 2009 by the Long Island Technology Hall of Fame. In January 2014, Dr. Hayward was given the David Award by Networking Magazine as one of eight of Long Island’s most accomplished individuals. Dr. Hayward has been a General Partner of Double D Venture Fund, a venture capital firm based in New York, New York. Dr. Hayward has served on the boards of many companies, the Stony Brook Foundation, the Research Foundation of the State of New York, the Long Island Association, the New York Biotechnology Association, the Long Island Life Sciences Initiative and the Ward Melville Heritage Foundation.
Follow James A. Hayward:
About Applied DNA Sciences: Applied DNA Sciences provides botanical DNA-based anti-counterfeiting and product authentication solutions.
Neil Desai
Founder, CEO and President of Aadi Bioscience
Neil is the Founder of Aadi Bioscience, Inc. He was former SVP, Global R&D, Abraxis Bioscience; VP, Strategic Platforms, Celgene Corp; Inventor of the nab® technology, Abraxane® and ABI-009. He successfully led the Abraxane team through all development stages. He has over 25 years of experience in novel therapeutic delivery systems with over 100 issued patents, over 40 peer-reviewed publications and book chapters, and over 200 presentations at scientific meetings. He is an active participant in FDA and EU Nanotechnology initiatives and a member of the Steering Committee for the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer. He holds board and advisory positions in various start-ups. He holds a M.S and Ph.D. in Chemical Engineering from the University of Texas at Austin, USA, and a B.S. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India.
Follow Neil Desai:
About Aadi Bioscience: Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Weston Daniel
Vice President of Translational Research of Exicure
Weston Daniel is the Vice President of Translational Research at Exicure.
Follow Weston Daniel:
About Exicure: Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Tom Walker
President & CEO of Rev1 Ventures
Tom Walker has been the Chief Executive Officer of TechColumbus, Inc. since May 2012. Tom Walker served as the Chief Executive Officer and President of i2E, Inc. until July 2012 and also served as its Chief Operating Officer and Executive Vice President. Tom Walker was responsible for the design and implementation of statewide and national programs and resources to assist advanced technology companies and entrepreneurs in business creation and access to early stage capital. Tom Walker served as the Chief Executive Officer and President at TechColumbus, Investment Arm. He has 15 years of experience building business opportunities in software, information technology, life sciences, alternative energy and the advanced materials industry sectors. He has a proven track record of coaching executive teams, as well as, raising and managing sources of early risk capital for emerging growth companies. As a Founding Member of i2E, Tom Walker was a Leader in the vision, design and implementation of i2E’s business units. He is responsible for the management of the Oklahoma Technology Commercialization Center and the Technology Business Finance Program, which are OCAST programs funded with state appropriations, as well as, the Reynolds Governor’s Cup Collegiate Business Plan Competition and Seed Step Angels. Tom Walker served as the Chief Executive Officer and Executive Director of the Oklahoma Investment Forum for three years, where he managed the Southwest Capital Conference. He serves as an Advisor to the National Angel Capital Association, serves as an Adjunct Professor of Entrepreneurship at the University of Tulsa and is a reviewer for the Kauffman Foundation’s eVenturing initiative. He served as an Editor and Publisher of the Future Value magazine. Tom Walker turned the financially failing organization around in one year and attracted in excess of $15 billion in venture capital from more than twenty states to the region. Prior to the formation of i2E, Tom Walker worked with Battelle Memorial Institute, where he managed the corporate business development for five national technology divisions of Battelle in the Oklahoma region. He was instrumental in the development of over $60 million in new technology development business, managed an advanced technology project portfolio that averaged $36 million over a six-year period and directly developed more than $15 million in scientific and engineering project sales. He is a frequent national and international speaker and advisor in the areas of building innovation and entrepreneurial infrastructures. Tom Walker serves on the Boards of National Angel Capital Educational Foundation, Leadership Oklahoma and the Oklahoma Alliance for Manufacturing Excellence. He served as Chairman of the 6th annual North American Angel Capital Summit and serves as Chairman of 7th annual Angel Capital Summit. He was recognized as one of the 2006 Oklahoma business leaders under the age of 40. Tom Walker holds a B.S. in Mechanical Engineering from the University of Oklahoma, and a Master’s of Business Administration from Oklahoma City University. He is a graduate of the 27th Annual Venture Capital Institute and the 4th Annual Venture Capital Institute Graduate Program. He is a graduate of Leadership Oklahoma Class XVIII.
Follow Tom Walker:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
R.Terry Dunlay
Founder, Chief Executive Officer & President of Intellicyt
Terry has a solid track record of leadership in the life sciences with over 25 years of experience in growing innovative technology companies and building value for customers, shareholders, and employees. Previously, he was co-founder and Executive Vice President of Cellomics, a leading provider of automated cellular analysis instruments, assays, and informatics software that was acquired by Fisher Scientific (now part of Thermo Fisher). At Cellomics, he invented and commercialized the company’s industry leading high content screening products. Prior to Cellomics, Terry was founder and CEO of Biological Detection, Inc. a bio-imaging software company and earlier was Vice President of Biological Detection Systems, Inc. a bio-imaging systems, software, and reagents company that was acquired by Amersham (now part of GE Healthcare). Former affiliations include Cytyc Corporation, Lockheed Martin, and PPG Industries. Terry has a BS and MS in Electrical Engineering and holds numerous patents in the area of cell-based screening instrumentation and informatics.
Follow R.Terry Dunlay:
About Intellicyt: IntelliCyt Corporation develops and markets high-throughput cell and bead-based screening solutions for the use of life sciences.
Aaron Kennington
Vice President of Engineering of Intellicyt
Follow Aaron Kennington:
About Intellicyt: IntelliCyt Corporation develops and markets high-throughput cell and bead-based screening solutions for the use of life sciences.
Ramsey Homsany
Co-Founder & President of Octant Bio
Ramsey Homsany is the founder and president of Octant Bio.
Follow Ramsey Homsany:
About Octant Bio: Octant Bio is a developer of synthetic technology used to improve health and treat disease.
Antony Koblish
Co-founder, President & Chief Executive Officer of TELA Bio
Antony Koblish is currently CEO and President of TELA Bio, a surgical reconstruction company he co-founded in 2012. Prior to TELA, he served as the Chief Executive Officer and President at Orthovita, a manufacturer of biologics for spinal surgery. Before his eleven-year tenure at Orthovita, where he was promoted to Chief Executive from Director of Worldwide Marketing, Antony served as Director of Marketing and Product Development in the Reconstructive Specialty Group at Howmedica. He currently serves as a Director of CeraPedics, Orthobond and The Pennsylvania Biotechnology Association.Antony has a B.S. in Mechanical Engineering from Worcester Polytechnic Institute and a M.S. in Engineering, Mechanical Engineering and Applied Mechanics from the University of Pennsylvania.
Follow Antony Koblish:
About Onkos Surgical, TELA Bio: TELA Bio is a life science company that specializes in soft tissue reconstruction.
Robert E. Dudley
Founder , Chairman, CEO and President of Clarus Therapeutics
Robert E. Dudley, Ph.D., has served as our Chief Executive Officer, President and Chairman of our board of directors since February 2004. Prior to that, from 2001 to 2003, he served as President, Chief Executive Officer, and Director of Anagen Therapeutics, Inc., a private biopharmaceutical company. He served as President, Chief Executive Officer, and Director of Unimed Pharmaceuticals, Inc. from 1999 to 2001 during which time Unimed received FDA approval for and launched AndroGel. From 1994 to 2001, Dr. Dudley held several senior level executive positions at Unimed Pharmaceuticals, Inc., a public company acquired by Solvay Pharmaceuticals in 1999. Dr. Dudley received his B.S. in Biology from Pepperdine University, Seaver College, his M.S. in Biology from University of New Mexico, and his Ph.D. in Pharmacology and Toxicology from the University of Kansas School of Medicine. Dr. Dudley is also a board-certified toxicologist. Dr. Dudley’s experience as a public company director and as a scientist with a leading role in commercializing the market leading T-replacement therapy, coupled with the insider’s perspective his role as our CEO brings to board discussions, provide him with the qualifications and skills to serve as a director.
Follow Robert E. Dudley:
About Clarus Therapeutics: Clarus Therapeutics is a biopharmaceutical company, develops androgen-based medicines for men and women.
Sina Adibi
CEO and President of Adaptive Clinical
Sina Adibi has over 25 years of experience in healthcare and life sciences informatics and business process outsourcing. Currently, as the CEO and founder of Adaptive Clinical Systems, Sina oversees all facets of the business from strategic planning, product development, sales and marketing, compliance and overall customer satisfaction of his revolutionary clinical trial data integration software. As a thought-leader in the healthcare industry, Sina frequently speaks at conferences and educates his constituency on clinical trial data protocol and efficacy. Sina held positions of leadership at a variety of leading healthcare companies. As Chief Technology Officer (CTO) at Paraxel, Inc., he was responsible for ideation, design and development of all facets of eClinical technology such as IVRS/ IWRS, EDC, CTMS, and medical imaging. As Senior Vice President for Systems and Technology and CTO at Thomson-Reuters Scientific and Healthcare, Sina had responsibility for scientific, technical, medical information management systems, data capture work flow systems, content enhancement, format setup, and publishing. As co-founder of Practical CTO, Inc., Sina concentrated on cloud-based information technology, workflow systems, and analytics. He was co-founder of superior Media Solutions, a business process and technology outsourcing company in the information publishing industry.
Follow Sina Adibi:
About Adaptive Clinical: Adaptive Clinical is a global life sciences technology company offers secure and cost-effective solution for clinical data integration.
Dimitrios Iliopoulos
CEO, President of Athos Therapeutics
Dimitrios Iliopoulos is the President and CEO at Athos.
Follow Dimitrios Iliopoulos:
About Athos Therapeutics, MedicusData.AI: Athos develops AI-based Precision Therapeutics for patients with Inflammatory Bowel, other Autoimmune Diseases, and cancer.
RA Session
President, Founder and CEO of Taysha Gene Therapies
RA Session II is the President, CEO and Founder of Taysha Gene Therapies. Mr. Session has nearly 20 years’ experience in the life sciences industry, primarily in business development, corporate strategy and financial roles. Previously, he served as Chief Business Officer of the gene therapy subsidiaries of BridgeBio, as well as Senior Vice President of Corporate Strategy and Business Development at AveXis.
Follow RA Session:
About Taysha Gene Therapies: Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Martin Cannon
President & CEO of New Health Sciences
Founder, President & CEO at Hemanext.
Follow Martin Cannon:
About Hemanext, New Health Sciences: New Health Sciences develops a technology to extend the shelf life of refrigerated red blood cells using novel storage methods.
Stephen Tierney
President of XiltriX North America
Stephen Tierney is the President at XiltriX North America.
Follow Stephen Tierney:
About XiltriX North America: XiltriX North America provides continuous development of real-time monitoring technologies for life science industries across the world.
Donna Dennis
Vice President of Nova Science Publishers
Follow Donna Dennis:
About Nova Science Publishers: A top academic publisher with high quality publications
Prem Premsrirut
Founder , President & CEO of Mirimus
Prem Premsrirut is an expert in the development and use of RNAi transgenic mice for fast and flexible validation and toxicity assessment of candidate genes targets in vivo. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice and pioneered a novel approach for the generation of “speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer. Dr. Premsrirut was an MD/PhD fellow at SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory. She received her Ph.D. in genetics and cancer biology following her training in the laboratory of Dr. Scott Lowe. Her work focused on the development of transgenic mouse models to study the effects of tumor maintenance on lung cancer using RNA interference. She received a B.A. in Molecular Cell Biology and Biochemistry from UC Berkeley. She previously worked in the lab of Dr. Ravi Iyengar at Mount Sinai School of Medicine, where she studied the downstream effects heterotrimeric G-proteins coupled to muscarinic, dopamine and adrenergic receptors in order to gain an understanding of the signal transduction pathways that play a role in opioid addiction and neuronal development.
Follow Prem Premsrirut:
About Mirimus: Mirimus is a producer of custom genetically-engineered mouse models with reverse gene silencing capabilities.
Alexander Kamb
President and CSO of A2 Biotherapeutics
Alexander Kamb is senior vice president, Discovery Research. In 2006, Kamb joined Amgen to direct Oncology Research at their South San Francisco site. He took over the leadership of the Neuroscience Therapeutic Area and was promoted to vice president, Research, and was given the remit to build a specialized department within Amgen Research (Genome Analysis Unit) focused on cross-disease-area applications of next-generation sequencing. Prior to joining Amgen, Kamb worked in the biotechnology field specializing in the genetics of cancer, then in the Pharmaceutical sector where he led the Novartis Oncology Research Group. Kamb received his A.B. from Harvard University and his Ph.D. from Caltech after a postdoctoral fellowship at UCSF.
Follow Alexander Kamb:
About A2 Biotherapeutics, Amgen: A2 Biotherapeutics develops novel medicines for serious illness.
Curt Weinstein
Vice President & General Manager of Corning
Follow Curt Weinstein:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Jeff Evenson
Executive Vice President & Chief Strategy Officer of Corning
Jeff Evenson is the Senior Vice President and Operations Chief of Staff for Corning, Inc. As a member of the 7-person Management Committee, Jeff has responsibilities including strategy implementation and special projects. Prior to joining Corning, Jeff was a senior sell-side analyst at Sanford Bernstein, where he was a consistent Institutional Investor All-Star in the Data Networking Sector. Prior to Corning, Jeff was a Partner at McKinsey & Company, where he was a leader in the technology strategy practice. During his career, Jeff has focused on strategy and finance for a broad range of technologies including data networking, smart grids, photonics, III-V semiconductors and drug discovery tools. Jeff holds an SB in Physics from MIT and a Ph.D. in Physics from Harvard, where he was a National Science Foundation Fellow. His thesis addressed the interaction of light and matter.
Follow Jeff Evenson:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Martin J. Curran
Innovation Officer – Executive Vice President of Corning
Marty Curran was appointed Corning’s first innovation officer in August 2012. In this role, Curran manages a portfolio of programs to increase the probability of success for new business opportunities. The innovation office was created to build an entrepreneurial-focused organization that could operate across all business segments to identify and develop near-term revenue opportunities. Over time, expectation is to streamline the innovation process where appropriate and increase speed-to-market. Curran joined Corning in 1984 and has held a variety of roles in finance, manufacturing, and marketing. He has served as senior vice president, general manager for Corning Cable Systems Hardware and Equipment Operations in the Americas of which he was responsible for operations in Hickory, N.C.; Keller, Texas; Reynosa, Mexico; Shanghai, China and the Dominican Republic. Curran led efforts to grow Corning’s Connectivity business, including the first major fiber-to-the home offering with Verizon FiOS. He has also served as senior vice president and general manager for Corning Optical Fiber and has served as Chairman of US Conec, a Corning Connectivity joint venture with Fujikura and NTT-AT. Curran graduated from the University of Notre Dame with a bachelor’s degree in finance and received his master’s degree from the University of Virginia’s Colgate Darden Graduate School of Business.
Follow Martin J. Curran:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Martin J. Curran
Innovation Officer – Executive Vice President of Corning
Marty Curran was appointed Corning’s first innovation officer in August 2012. In this role, Curran manages a portfolio of programs to increase the probability of success for new business opportunities. The innovation office was created to build an entrepreneurial-focused organization that could operate across all business segments to identify and develop near-term revenue opportunities. Over time, expectation is to streamline the innovation process where appropriate and increase speed-to-market. Curran joined Corning in 1984 and has held a variety of roles in finance, manufacturing, and marketing. He has served as senior vice president, general manager for Corning Cable Systems Hardware and Equipment Operations in the Americas of which he was responsible for operations in Hickory, N.C.; Keller, Texas; Reynosa, Mexico; Shanghai, China and the Dominican Republic. Curran led efforts to grow Corning’s Connectivity business, including the first major fiber-to-the home offering with Verizon FiOS. He has also served as senior vice president and general manager for Corning Optical Fiber and has served as Chairman of US Conec, a Corning Connectivity joint venture with Fujikura and NTT-AT. Curran graduated from the University of Notre Dame with a bachelor’s degree in finance and received his master’s degree from the University of Virginia’s Colgate Darden Graduate School of Business.
Follow Martin J. Curran:
About Corning: Corning is a manufacturer of building materials including glass, ceramic, related materials and technologies, and more.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Feng Tian
Chief Executive Officer and President of Ambrx
Feng Tian, Ph. D. is the Chief Executive Officer and President of Ambrx. He has held positions of increasing responsibility since the beginning of Ambrx. Previously, as Chief Scientific Officer Dr. Tian oversaw the company’s research and development. During his tenure at Ambrx, Dr. Tian has been instrumental in the establishment and improvement of Ambrx technology and product platforms. He played a key role in the establishment of the EuCODE technology platform (site-specific non-natural amino acid incorporation in eukaryotic cells). Additionally, he led multiple teams to establish Ambrx’s site-specific antibody drug conjugate (ADC) technology platform, the bi-specific antibody platform, and the “Life Switch” vaccine platform. Dr. Tian also initiated and established the Ambrx China Strategy. He played a central role in building China collaborations, and more recently, in Ambrx strategic transactions in 2015. Prior to joining Ambrx, Dr. Tian conducted his post-doctoral study at The Scripps Research Institute in Professor Peter G. Schultz’s group, where his work involved catalytic antibodies, non-natural amino acid incorporation, and biosensors. Dr. Tian received his Ph.D. in Chemistry from the University of Florida, with a dissertation in the field of Physical Organic Chemistry, under the supervision of Professor William R. Dolbier, Jr. He received his B. S. in Chemistry from Peking University.
Follow Feng Tian:
About Ambrx: Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
Dana Zhang
Vice-President of Finance of Ambrx
Seasoned financial and operational executive with 20 years of pharmaceutical industry and international business experience. Result driven with an emphasis on finance, operations, process improvement and business development. Experience with marketing partnerships, acquisitions and debt and equity financing.
Follow Dana Zhang:
About Ambrx: Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
Anthony D. Piscopio
Co-Founder, President & CEO of OnKure
Tony Piscopio is an OnKure co-founder and has served as Chief Executive Officer and a member of the OnKure Board of Directors since its founding in April, 2011. Dr. Piscopio is a serial entrepreneur with executive leadership experience spanning a 23 year career in the life sciences industry. Most recently, he served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation. Prior to this, Dr. Piscopio co-founded Array BioPharma (ARRY;NASDAQ) where he served as V.P. of Chemistry and was responsible for strategy, new product development, GMP manufacturing, process research, parallel synthesis on an industrial scale and oncology drug discovery. Prior to founding Array, Dr. Piscopio was a founding member of Amgen’s small molecule drug discovery division, Boulder, CO, and served as a research scientist at Pfizer. Dr. Piscopio was an NIH Postdoctoral Fellow at The Scripps Research Institute and received his Ph.D. at the University of Wisconsin-Madison.
Follow Anthony D. Piscopio:
About OnKure: OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs.
